These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28460165)

  • 41. Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel.
    Jain S; Kumar D; Swarnakar NK; Thanki K
    Biomaterials; 2012 Oct; 33(28):6758-68. PubMed ID: 22748771
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characteristics and behaviour of liposomes when incubated with natural bile salt extract: implications for their use as oral drug delivery systems.
    Hermida LG; Sabés-Xamaní M; Barnadas-Rodríguez R
    Soft Matter; 2014 Sep; 10(35):6677-85. PubMed ID: 25060405
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Liposome (Lipodine)-mediated DNA vaccination by the oral route.
    Perrie Y; Obrenovic M; McCarthy D; Gregoriadis G
    J Liposome Res; 2002; 12(1-2):185-97. PubMed ID: 12604053
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the physical properties and stability of two lipid drug delivery systems containing mefloquine.
    Slabbert C; Plessis LH; Kotzé AF
    Int J Pharm; 2011 May; 409(1-2):209-15. PubMed ID: 21310223
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Investigation of factors affecting controlled release from photosensitive DMPC and DSPC liposomes.
    Aygun A; Torrey K; Kumar A; Stephenson LD
    Appl Biochem Biotechnol; 2012 Jun; 167(4):743-57. PubMed ID: 22592778
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nanocrystal-Loaded Lipid Carriers for Improved Oral Absorption and Anticancer Efficacy of Etoposide: Formulation Development, Transport Mechanism, In Vitro and In Vivo Evaluation.
    Wang Y; Wang P; Li H; Han X; Zhu H; Jin X
    Mol Pharm; 2024 Mar; 21(3):1170-1181. PubMed ID: 38329909
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties.
    Krishna R; Webb MS; St Onge G; Mayer LD
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1206-12. PubMed ID: 11504822
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development and Characterization of the Solvent-Assisted Active Loading Technology (SALT) for Liposomal Loading of Poorly Water-Soluble Compounds.
    Pauli G; Tang WL; Li SD
    Pharmaceutics; 2019 Sep; 11(9):. PubMed ID: 31505795
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt.
    Chen Y; Lu Y; Chen J; Lai J; Sun J; Hu F; Wu W
    Int J Pharm; 2009 Jul; 376(1-2):153-60. PubMed ID: 19394416
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preparation, characterization and in vitro evaluation of sterically stabilized liposome containing a naphthalenediimide derivative as anticancer agent.
    Parise A; Milelli A; Tumiatti V; Minarini A; Neviani P; Zuccari G
    Drug Deliv; 2015; 22(5):590-7. PubMed ID: 24286206
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro and in vivo correlation of disintegration and bitter taste masking using orally disintegrating tablet containing ion exchange resin-drug complex.
    Kim JI; Cho SM; Cui JH; Cao QR; Oh E; Lee BJ
    Int J Pharm; 2013 Oct; 455(1-2):31-9. PubMed ID: 23933050
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Stability of SUV liposomes in the presence of cholate salts and pancreatic lipases: effect of lipid composition.
    Kokkona M; Kallinteri P; Fatouros D; Antimisiaris SG
    Eur J Pharm Sci; 2000 Jan; 9(3):245-52. PubMed ID: 10594380
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improved oral bioavailability of alendronate via the mucoadhesive liposomal delivery system.
    Han HK; Shin HJ; Ha DH
    Eur J Pharm Sci; 2012 Aug; 46(5):500-7. PubMed ID: 22522117
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes).
    Jain S; Patil SR; Swarnakar NK; Agrawal AK
    Mol Pharm; 2012 Sep; 9(9):2626-35. PubMed ID: 22871060
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced tumor targeting of doxorubicin by ganglioside GM1-bearing long-circulating liposomes.
    Unezaki S; Maruyama K; Ishida O; Takahashi N; Iwatsuru M
    J Drug Target; 1993; 1(4):287-92. PubMed ID: 8069570
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preparation and evaluation of lyophilized liposome-encapsulated bufadienolides.
    Li F; Yang R; Weng Y; Tang X
    Drug Dev Ind Pharm; 2009 Sep; 35(9):1048-58. PubMed ID: 19365782
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liposomal formulations for oral immunotherapy: in-vitro stability in synthetic intestinal media and in-vivo efficacy in the mouse.
    Ouadahi S; Paternostre M; André C; Genin I; Thao TX; Puisieux F; Devissaguet JP; Barratt G
    J Drug Target; 1998; 5(5):365-78. PubMed ID: 9771618
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone.
    Lim HJ; Masin D; Madden TD; Bally MB
    J Pharmacol Exp Ther; 1997 Apr; 281(1):566-73. PubMed ID: 9103545
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preparation and characterization of doxorubicin liposomes.
    Niu G; Cogburn B; Hughes J
    Methods Mol Biol; 2010; 624():211-9. PubMed ID: 20217598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.